Veligrotug labeling shows data for both the active and chronic forms of TED

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

The FDA approved Lumvoa, a full insulin-like growth factor 1 receptor antagonist, for the treatment of thyroid eye disease, according to a press release from Viridian…

Veligrotug labeling shows data for both the active and chronic forms of TED

FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.